Brief: Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves ETRASIMOD For Adults With Moderately To Severely Active Ulcerative Colitis
16/10/2023 24:53
Oct 15 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES' LICENSING PARTNER PFIZER ANNOUNCES U.S.
FDA
APPROVES ETRASIMOD FOR ADULTS WITH MODERATELY TO SEVERELY ACTIVE
ULCERATIVE COLITIS
* EVEREST MEDICINES- CO IS CONDUCTING MULTI-CENTER PHASE 3
CLINICAL TRIAL OF ETRASIMOD IN ASIA AND AIMS TO FILE NEW DRUG
APPLICATION AS SOON AS POSSIBLE
Source text for Eikon: ID:nPnDlwCMa
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region